Patient P-02151

Synthetic patientMETA-24 · Day 172 · 25–34 · M · baseline S04Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Improving

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

55%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S04
Day 63 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 122 CR-01 recommended — Clinician Review CR-01
Day 123 Patient accepted — Started CR-01 in the companion
Day 128 Deterioration detected before clinical escalation — Clinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 63.

Primary contributors, last 14 days

Treatment adherence+7
Toxicity-7
Inflammatory activity-6
GI instability-5
Nutritional resilience+3

What helped?

Clinician Review CR-01Day 122
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

58%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

59 min

stable · -0.1 vs previous 14 d

Sleep duration

Wearable

5.9 h

stable · +0.0 vs previous 14 d

Energy level

Daily log

3.4/10

improving · +0.1 vs previous 14 d

Steps

Wearable

6,382

stable · +140 vs previous 14 d

GI burden

Companion

56.1/100

stable · -2.3 vs previous 14 d

Adherence

Companion

67.2 %

stable · -0.2 vs previous 14 d

Sleep quality

Wearable

18/100

stable · +0.7 vs previous 14 d

Glucose, CGM daily mean

CGM

142 mg/dL

stable · -0.7 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 29 from the failing basin, 60 from restoration.

Good elements to keep

Clinician Review CR-01
intervention · steering +7.8
Protein (supports)
perturbation · steering +6.3
Daily walks resumed
perturbation · steering +3.3
Protein
supporter · GI -3.5 next day

Main detractors to watch

Low butyrate capacity
hidden · steering -17.5
FUT2 non-secretor
hidden · steering -10.6
Low microbial diversity
hidden · steering -7.7
IL6 high-expression variant
hidden · steering -7.3
Dietary fat load
detractor · GI +3.3 next day
Histamine load
detractor · GI +2.6 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-3.5supporter · 95%
Dietary fat load
+3.3detractor · 95%
Histamine load
+2.6detractor · 95%
Ultra-processed food
+2.6detractor · 95%
Simple carbohydrates
+1.6detractor · 59%
Alcohol
+0.8no signal · 29%
Insoluble fibre
-0.3no signal · 15%
Caffeine
-0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 5.9 h, below personal baseline
Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 59
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 33/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 53

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 19 ms
Sleep: 6.7 h
Steps: 5,895
Resting HR: 83 bpm

Daily log: GI score 56, nutritional resilience 40, adherence 67.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02483	21%	S06	BR-03	no change	64
P-02087	19%	S01	BR-03	no change	40
P-02025	42%	S15	CR-01	improved	61
P-02054	41%	S01	CR-01	improved	57
P-02009	32%	S08	CR-01	improved	64
P-02233	30%	S16	CR-01	improved	66
P-02154	29%	S16	CR-01	improved	57
P-02395	21%	S12	DT-01	improved	57
P-02491	21%	S09	DT-01	no change	65
P-02274	20%	S15	DT-01	improved	50
P-02339	20%	S03	DT-01	improved	50
P-02084	49%	S11	GI-04	no change	58